Key Highlights

  • Capricor Therapeutics (NASDAQ:CAPR) closed at USD 7.83 in the October 9, 2026 session, down USD 0.18 or 2.25%, with a market value of USD 465.693 million according to published market data.
  • Volume was 2.509M shares against a three-month average of 6.849M, about 0.37 times normal, simple arithmetic on two published numbers, so the decline came on quieter trading than usual.
  • The stock appears on both a most shorted screen and an aggressive small cap screen, with one-year earnings per share growth of 48.91% and a 52-week range of USD 2.96 to USD 40.37.
  • No company-specific catalyst was identified for the session, and the move reflects published market data rather than a confirmed announcement from Capricor. Regulatory developments should be confirmed in company filings.

A Biotech That Sits on Two Different Lists of Interest

Capricor Therapeutics (NASDAQ:CAPR) develops cell and exosome therapeutics, and its lead candidate deramiocel targets cardiomyopathy linked to Duchenne muscular dystrophy. The shares appear on two published market screens at once. One covers names with high short interest positions, and the other covers companies with market value below USD 2 billion and one-year earnings per share growth of at least 25%, which for CAPR is 48.91%. Earnings growth at a clinical-stage company usually reflects changes in a small base, such as grant or collaboration income or lower costs, so it should not be read as a sign of a mature profit stream. The two screens describe the same company from opposite angles.

Reading a Price Far Below the 52-Week High

At USD 7.83, Capricor Therapeutics (NASDAQ:CAPR) trades roughly 81% below its 52-week high of USD 40.37 and about 2.6 times its 52-week low of USD 2.96, simple arithmetic on published numbers. That wide range shows how sharply regulatory news can reprice a development-stage company. Biotech shares often rise or fall by large amounts when an agency decision, trial result or filing outcome becomes public, because the value of the company rests on a small number of programs. A lower price after a spike can also leave a stock with a large pool of holders who bought higher, which can add selling pressure on weak days and make recoveries uneven.

What High Short Interest Means for CAPR

High short interest means many traders have borrowed shares and sold them in the expectation of a lower price. They must eventually buy the shares back, so a surprise rise can force covering and push the price higher, which is called a short squeeze. The reverse is also possible, because shorts can add to pressure when sentiment turns. Capricor Therapeutics (NASDAQ:CAPR) fell on volume below average in the session, which does not suggest a squeeze was under way. Short interest figures are reported twice a month and lag the market, so any conclusion about positioning should be checked against the latest exchange data before it is relied on. A decline on light volume, as seen here, is usually weaker evidence than one on heavy trading.

Where Things Stand

Capricor Therapeutics (NASDAQ:CAPR) is down 2.25% because the published data show a quiet decline on light volume, and no company-specific catalyst was identified for the October 9, 2026 session. Context matters for a shorted biotech this week, with the S&P 500 at 7,811.5 just below its record, the 10-year Treasury yield near 5.25%, and the Consumer Price Index report due October 14 at 8:30 a.m. ET. Rate-sensitive, cash-consuming development companies tend to feel higher yields most. Regulatory news remains the main driver of CAPR over time.